Celltrion Pharm and Douzone Bizon Join MSCI... Hanjin Kal Excluded

Hanjin KAL Seems Burdened by Low Free Float Ratio

[Asia Economy Reporter Minji Lee] Celltrion Pharm and Douzone Bizon have been added to the Morgan Stanley Capital International (MSCI) Korea Index components. Hanjin KAL, which had raised expectations, was not included.

According to the financial investment industry on the 13th, MSCI, a global stock index provider, included Celltrion Pharm and Douzone Bizon in the Korea Index components in the standard index regular rebalancing announced that day. Conversely, OCI, Medytox, HDC Hyundai Development Company, KCC, and Hanwha Life were excluded from the index.

In the case of Hanjin KAL, a low free float ratio acted as a limiting factor, preventing its inclusion in the index.

The index changes will be applied after the market close on the 29th. With this change, Korea's weight in the emerging markets index decreased from 12.9% to 12.6%, while China's increased from 40.5% to 41.5%.

Kang Songcheol, a researcher at Shinhan Financial Investment, explained, "There will likely be a selling bias on Korean stocks on the regular change application date," adding, "Besides the inclusions, Celltrion Healthcare, Kakao, HL Biopharma, CJ, Hyundai Steel, and Samsung Heavy Industries increased their weights due to changes in free float (FIF) and number of shares, while Naver, POSCO, and Mirae Asset Daewoo saw their weights decrease."

This content was produced with the assistance of AI translation services.